e-learning
resources
Copenhagen 2005
Wednesday 21.09.2005
Cystic fibrosis lung disease: let's make things better
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
8-iso Prostaglandin F
2
a
and sCD163 in bronchoalveolar lavage fluid of patients with cystic fibrosis under therapy with recombinant DNAse
M. Timmermann, E. Rietschel, K. Paul, P. Högger (Würzburg, Köln, Germany)
Source:
Annual Congress 2005 - Cystic fibrosis lung disease: let's make things better
Session:
Cystic fibrosis lung disease: let's make things better
Session type:
Poster Discussion
Number:
4631
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Timmermann, E. Rietschel, K. Paul, P. Högger (Würzburg, Köln, Germany). 8-iso Prostaglandin F
2
a
and sCD163 in bronchoalveolar lavage fluid of patients with cystic fibrosis under therapy with recombinant DNAse. Eur Respir J 2005; 26: Suppl. 49, 4631
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Concentration of sFas in bronchoalveolar lavage fluid of smoking patients with sarcoidosis
Source: Annual Congress 2012 - Sarcoidosis
Year: 2012
High level of leukotriene B4 in bronchoalveolar lavage fluid is associated with poor prognosis in patients with interstitial pneumonia
Source: Annual Congress 2010 - Usefulness of bronchoalveolar lavage in diffuse parenchymal lung disease
Year: 2010
The analysis of tryptase in serum and bronchoalveolar lavage of sarcoidosis patients
Source: Annual Congress 2008 - Role of bronchoalveolar lavage in studying the pathophysiology of interstitial lung disease
Year: 2008
Elevated NT-3 levels in bronchoalveolar lavage fluid of patients with pulmonary sarcoidosis
Source: Eur Respir J 2007; 30: Suppl. 51, 586s
Year: 2007
Cytokine profiles of bronchoalveolar lavage fluid in patients with combined pulmonary fibrosis and emphysema
Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis
Year: 2012
ECP and EPX in bronchoalveolar lavage fluid in children with cystic fibrosis and mild lung disease
Source: Eur Respir J 2001; 18: Suppl. 33, 538s
Year: 2001
Levels of antimicrobial peptide LL-37 in BALF and ELF from patients with pulmonary fibrosis
Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease
Year: 2013
Soluble Fas-ligand levels in bronchoalveolar lavage fluid before and after interferon-γ-1b treatment in idiopathic pulmonary fibrosis
Source: Eur Respir J 2005; 26: Suppl. 49, 334s
Year: 2005
Th1/Th2/Th17-related cytokines in the bronchoalveolar lavage fluid of patients with sarcoidosis in relation to smoking
Source: Annual Congress 2012 - Diffuse parenchymal lung disease I
Year: 2012
CCL20 level in bronchoalveolar lavage fluid is correlated with the levels of serum indications in patients with pulmonary sarcoidosis
Source: Annual Congress 2010 - Usefulness of bronchoalveolar lavage in diffuse parenchymal lung disease
Year: 2010
The impact of smoking on bronchoalveolar lavage fluid (BALf) amyloid A concentration in patients with sarcoidosis
Source: Annual Congress 2013 –Sarcoidosis and other granulomatosis
Year: 2013
Elevated TGF- b1 concentration in bronchoalveolar lavage fluid from patients with primary lung cancer
Source: Eur Respir J 2002; 20: Suppl. 38, 585s
Year: 2002
Mast cell tryptase concentration measured with B12 antibody-based immunoassay in bronchoalveolar lavage fluid from patients with interstitial lung disease
Source: Eur Respir J 2004; 24: Suppl. 48, 10s
Year: 2004
Tryptase levels in bronchoalveolar lavage fluid (BALF) may predict the recurrence and chronicity of eosinophilic pneumonia
Source: International Congress 2019 – Immunopathological mechanisms of lung disease
Year: 2019
Levels of interferon-γ and interleukin-2 receptor-α for bronchoalveolar lavage fluid were correlated with clinical grade and treatment course of pulmonary tuberculosis
Source: Eur Respir J 2001; 18: Suppl. 33, 466s
Year: 2001
Cathelicidin (LL-37) ve human β2 defensin levels in bronchoalveolar fluid of pediatric patients with non-cystic fibrosis bronchiectasis
Source: International Congress 2015 – Paediatric pulmonary infections
Year: 2015
High levels of pepsin A in bronchoalveolar lavage fluid of patients with exacerbation of interstitial lung diseases and no evidence of infection
Source: Annual Congress 2010 - Usefulness of bronchoalveolar lavage in diffuse parenchymal lung disease
Year: 2010
Elastase and α1-proteinase inhibitor in bronchoalveolar lavage fluid of children with chronic bronchiolitis
Source: Eur Respir J 2001; 18: Suppl. 33, 181s
Year: 2001
The level of bronchoalveolar lavage fluid prostaglandine E2; Is it diagnostic of bronchogenic carcinoma?
Source: Annual Congress 2013 –Progress in bronchoscopy and pathology techniques for diagnosis of thoracic malignancies
Year: 2013
Interleurin-4 and immunoglobulin E levels in bronchoalveolar lavage fluid and blood serum in patients with bronchial asthma and lung tuberculosis
Source: Eur Respir J 2001; 18: Suppl. 33, 271s
Year: 2001
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept